Invention Grant
- Patent Title: Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
-
Application No.: US15126997Application Date: 2015-03-19
-
Publication No.: US10005765B2Publication Date: 2018-06-26
- Inventor: Yun Long
- Applicant: Capella Therapeutics, Inc.
- Applicant Address: US CA San Diego
- Assignee: Capella Therapeutics, Inc.
- Current Assignee: Capella Therapeutics, Inc.
- Current Assignee Address: US CA San Diego
- Agency: Jones Day
- International Application: PCT/US2015/021455 WO 20150319
- International Announcement: WO2015/143148 WO 20150924
- Main IPC: C07D233/04
- IPC: C07D233/04 ; A61K31/55 ; C07D409/14 ; C07D223/04 ; C07D401/14 ; C07D405/14 ; C07D403/04 ; C07D403/14 ; C07D403/12
Abstract:
Provided herein are benzimidazole derivatives, for example, of Formula I, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.
Public/Granted literature
- US20170183330A1 BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER Public/Granted day:2017-06-29
Information query
